Akt3 degrader 1 can be used for the study of drug-resistant non-small cell lung cancer (NSCLC); it overcomes Osimertinib-induced resistance in H1975 OR NSCLC cells and exhibits antiproliferative activity by significantly inhibiting tumor growth in mice.